ST. LOUIS, April 7, 2010 (GLOBE NEWSWIRE) -- Murphy Analytics (MA) has updated sponsored research coverage on NeoStem, Inc. (AMEX:NBS). The Update Report contains a detailed discussion of the NBS business model, market dynamics, financial results and risks. The Update Report is available at http://www.murphyanalytics.com/uploads/NBS_Update.
Analyst Patrick J. Murphy, CFA notes in the report: "Founded over fifty years ago, NBS 51% owned subsidiary Erye Pharmaceutical Company has a proven operating history that positions the Company to take advantage of the PRC government's stated objective of spending $124 billion from 2009 - 2011 to expand health care to 90% of the country's population with an emphasis on the 900 million rural population. The acquisition of Erye has transformed NBS into a multi-dimensional international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units."
About Murphy Analytics
Murphy Analytics is an independent investment research firm providing coverage of microcap and smallcap stocks. Utilizing institutional caliber, fundamental, bottom-up analysis, Murphy Analytics helps investors make informed investment decisions about equities without extensive analyst coverage, with a focus on small-cap and micro-cap public stocks. Murphy Analytics LLC is owned by Patrick J. Murphy, who has over 15 years of capital markets experience, providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's.
Disclosure: Neither Murphy Analytics (MA) nor the analyst owns or trades the shares of covered companies. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. MA provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. This sponsored research report represents neither a solicitation to buy nor an offer to sell securities and is to be used for informational purposes only and should not be used as basis for investment decisions. MA is not an investment advisor or broker/dealer and this report does not provide investment advice.